Blue Jet Healthcare shares tumbled more than 8% today after the company posted disappointing Q2 FY25 results. As of 12:54 PM, the shares were trading 8.46% higher at Rs 617.00.
The pharmaceutical firm’s consolidated net profit declined 10.8% year-on-year to ₹52 crore, compared to ₹58.3 crore in the same quarter last year.
Revenue dropped 20.6% YoY to ₹165.4 crore from ₹208.2 crore, signaling a slowdown in business momentum. EBITDA also slipped 21% to ₹55 crore, though margins stayed steady at 33.1% versus 33.3% a year earlier, reflecting effective cost management despite weaker topline performance.
Blue Jet Healthcare stock opened at ₹680 and touched an intraday high of ₹688.50 before sliding to a low of ₹617.45. The counter remains under pressure, with investors reacting negatively to the muted growth outlook. The stock’s 52-week range stands between ₹1,027.80 and ₹468.50.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
